奥美沙坦酯治疗原发性高血压的疗效和安全性

Effect and Safety of Olmesartan medoxomil on Treatment of Essential Hypertension

目的:评价奥美沙坦酯治疗原发性高血压的疗效和安全性。方法:选择轻、中度高血压患者64例,随机分为奥美沙坦酯治疗组(n=34例)和缬沙坦对照组(n=30例),每日1次口服奥美沙坦酯20 mg或缬沙坦80 mg,2周后如舒张压≥90mmHg,则剂量加倍,进行8周的临床观察。结果:两组患者血压均得到明显降低(P<0.01),奥美沙坦酯组,总有效率88.2%;缬沙坦组总有效率86.7%。两组比较无统计学差异(P>0.05)。结论:奥美沙坦酯治疗原发性高血压疗效显著,与进口同类药缬沙坦相当,不良反应少,安全有效。

Objective： To evaluate the curative effect and the safety of olmesartan medoxomil on the treatment of essential hypertension. Method： Sixty-four patients with mild and moderate hypertension were randomly divided into olmesartan medoxomil treatment group（ n = 34） and valsartan control group （n = 30） . They were given olmesartan medoxomil 20 mg or valsartan 80mg po, qd. If patients＇DBP≥90 mmHg after two weeks later,then the doses would be double. Clinical obervation was carried out for 8 weeks. Result： Blood pressure of two group of patients were all obviously decreased （P 〈 0.01 ）. The total effective rate of olmesartan medoxomil group was 88.2% ; and 86.7% in vlsartan group. There were no statistical difference between two groups （P 〉 0.05 ）. Conclusion： Olmesartan medoxomil has obvious curative effect on essential hypertension, its effect is corresponding to that of import valsartan. Olmesartan medoxomil is proved to be safe with less adverse reactions.